This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jin, F.-Y. Articles by Kashyap, M. L. Search for Related Content PubMed PubMed Citation Articles by Jin, F.-Y. Articles by Kashyap, M. L. Related Collections Cardiovascular Pharmacology Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:1051-1059.)
© 1999 American Heart Association, Inc.

Original Contributions

Niacin Accelerates Intracellular ApoB Degradation by Inhibiting Triacylglycerol Synthesis in Human Hepatoblastoma (HepG2) Cells

Fu-You Jin; Vaijinath S. Kamanna; Moti L. Kashyap

From the Cholesterol Center, Medical Service, Department of Veterans Affairs Medical Center, Long Beach, Calif (F.-Y.J., V.S.K., M.L.K.), University of California, Irvine, Calif (F.-Y.J., V.S.K., M.L.K.) and National University of Singapore (M.L.K.).

Correspondence to Moti L. Kashyap, MD, Director, Cholesterol Center, Department of Veterans Affairs Medical Center, 5901 E Seventh Street (111GE), Long Beach, CA 90822.

Abstract—The mechanism by which the potent drug niacin decreases apoB-containing atherogenic lipoproteins and prevents coronary disease is unclear. Utilizing human hepatoblastoma (HepG2) cells as an in vitro model, we have examined the effect of niacin on intracellular degradation of apoB and the regulatory mechanisms involved in apoB processing. Niacin significantly increased apoB degradation in a dose- and time-dependent manner. Treatment of HepG2 cells with calpain inhibitor I [N-acetyl-leucyl-leucyl-norleucinal (ALLN), an inhibitor of certain protease-mediated apoB degradation], did not alter niacin-induced apoB degradation. Niacin decreased inhibition of oleate-mediated apoB degradation. Niacin dose-dependently inhibited the synthesis of both fatty acids and triacylglycerol (TG) by 20% to 40% as determined by the incorporation of ¹⁴C-acetate and ³H-glycerol into fatty acids and TG, respectively. Incubation of HepG2 cells with niacin significantly inhibited (by 12% to 15%) fatty acid esterification to produce TG as assessed by the incorporation of ³H-oleic acid into TG. ¹⁴C-acetate incorporation into cholesterol and phospholipids was unchanged. The activity of microsomal triglyceride transfer protein (MTP), a carrier protein for lipids, was not altered by pretreatment of cells with niacin. ApoB mRNA expression and ¹²⁵I-LDL protein uptake were also unchanged. These data indicate that niacin accelerates hepatic intracellular post-translational degradation of apoB by selectively reducing triglyceride synthesis (through inhibiting both fatty acid synthesis and fatty acid esterification to produce TG) without affecting ALLN-inhibitable protease- or MTP-mediated intracellular apoB processing, resulting in decreased apoB secretion and hence lower circulating levels of the atherogenic lipoproteins.

Key Words: atherosclerosis • coronary disease • hepatic apoB degradation • niacin • fatty acid • triacylglycerol

This article has been cited by other articles:

				S. H. Ganji, S. Tavintharan, D. Zhu, Y. Xing, V. S. Kamanna, and M. L. Kashyap Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells J. Lipid Res., October 1, 2004; 45(10): 1835 - 1845. [Abstract] [Full Text] [PDF]

				M. E Mcgovern Review: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome The British Journal of Diabetes & Vascular Disease, March 1, 2004; 4(2): 78 - 85. [Abstract] [PDF]

				G. PERLEMUTER, A. SABILE, P. LETTERON, G. VONA, A. TOPILCO, Y. CHRETIEN, K. KOIKE, D. PESSAYRE, J. CHAPMAN, G. BARBA, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis FASEB J, February 1, 2002; 16(2): 185 - 194. [Abstract] [Full Text] [PDF]